

# CUDC-427

Catalog No: tcsc3392



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

1446182-94-0

**Formula:**

$C_{29}H_{36}N_6O_4S$

**Pathway:**

Apoptosis

**Target:**

IAP

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 61$  mg/mL (108.02 mM)

**Alternative Names:**

GDC-0917

**Observed Molecular Weight:**


564.7

## Product Description

CUDC-427 is a potent second-generation pan-selective **IAP** antagonist, used for treatment of various cancers.

**In Vitro:** GDC-0917 (0.1 nM-10  $\mu$ M) induces reduction of cIAP1 levels in PBMCs in a concentration-dependent manner showing greater than 80% inhibition at concentrations greater than 0.1  $\mu$ M (56.5 ng/mL)<sup>[1]</sup>.

**In Vivo:** GDC-0917 (0.08-16.3 mg/kg) exhibits antitumor activity in a dose dependent manner in the MDA-MB-231-X1.1 Breast Cancer Xenograft, and GDC-0917 is well tolerated, with all dose groups experiencing a [1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!